Exelixis has named J. Scott Garland as executive vice president and chief commercial officer. As the company's chief commercial officer, Gardland will oversee the commercial functions of marketing, sales and commercial operations, and collaborate closely with Exelixis' development and manufacturing teams to provide commercial perspective for cabozantinib development efforts across multiple oncology indications.

Garland comes to Exelixis from Genentech, where he served as vice president of its Avastin franchise. Prior to that position, he served as vice president, hematology marketing and sales, overseeing the Rituxan franchise and as a director on the Tarceva franchise.